Abstract
The global pandemic of the Corona virus disease (COVID-19) has caused widespread morbidity and mortality globally. The
complicated pathophysiology of COVID-19 and lack of a single therapy have made management a significant issue. Through
comprehensive pharmacological, toxicological, and clinical research, AYUSH-64, a poly-herbal formulation developed by CCRAS,
ministry of AYUSH, government of India, has demonstrated both its safety and effectiveness in treating infective febrile illnesses like malaria
and influenza. Four components in AYUSH-64 include antiviral, immunomodulatory, anti-inflammatory, antipyretic, and anti-inflammatory
properties. In COVID-19, it stops the inflammatory responses that lead to substantial morbidity. The government of India has also included
AYUSH-64 in the National COVID management protocol based on Ayurveda and Yoga for asymptomatic and mild cases of COVID-19.
The study summarizes the therapeutic potential of AYUSH-64 on the basis of clinical trials conducted in India on COVID-19
Users
Please
log in to take part in the discussion (add own reviews or comments).